'김갑성' 기자의 전체기사
-
Zoomlion's Corporate-Named Satellite Enters Orbit, Marking a N…
RIZHAO, China, Aug. 11, 2025 -- Zoomlion Heavy Industry Science & Technology Co., Ltd. ("Zoomlion," 1157.HK) has reached a new milestone with the successful entry into orbit of the "Zoomlion" corporate-named satellite, the first of its kind in the global engineering machinery sector. At 00:31 Beijing time, the Geely Constellation Group 04 satellites were launched from the coastal waters near Rizhao, Shandong, China, using the Jielong-3 carrier rocket, with one satellite carrying the Zoomlion name. The "Zoomlion" satellite marks the company's ex
- 김갑성 기자
- 2025-08-11 16:26
-
Akeso Announces First Patient Dosed in Phase III Trial of Ivon…
HONG KONG, Aug. 11, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter, randomized, double-blind Phase III study (AK112-311/HARMONi-9), evaluating ivonescimab, a first-in-class PD-1/VEGF bispecific antibody developed by Akeso, in small cell lung cancer (SCLC). This study is designed to assess the efficacy and safety of ivonescimab as consolidation therapy in patients with limited-stage small cell lung cancer (LS-SCLC) who have not experienced progression following standard concurrent chemoradiotherapy
- 김갑성 기자
- 2025-08-11 10:52
-
Philippines' AC Health partners with Singapore's ABC Impact in…
MANILA, Philippines, Aug. 11, 2025 -- AC Health, the healthcare arm of Ayala Corporation, has secured a landmark investment from ABC Impact, the Singapore-based impact investor dedicated to Asia and backed by Temasek Trust and Temasek. This strategic investment marks ABC Impact's entry into the Philippine healthcare sector, expanding its regional footprint. Under the agreement, ABC Impact will infuse primary capital for a c.16% minority stake in AC Health. The investment will support AC Health's vision of transforming healthcare for every Filipino by building a se
- 김갑성 기자
- 2025-08-11 10:31
-
HistoIndex Marks Another Step Forward with FibroSIGHT™ Plus:…
SINGAPORE, Aug. 11, 2025 -- HistoIndex, a pioneering leader in digital pathology solutions for chronic liver disease, has announced the launch of FibroSIGHT™ Plus, its second Laboratory Developed Test (LDT) available in the United States. Building on the foundation of FibroSIGHT™[1], which debuted just months earlier, FibroSIGHT™ Plus introduces an additional feature of automated quantitative analysis of fibrosis - a key advancement that enables more consistent and precise characterization at diagnosis and tracking of fibrosis in patients with Metabolic Dysfunction-associated Steatohepatitis
- 김갑성 기자
- 2025-08-11 09:00
-
Brain Navi Biotechnology's NaoTrac performs first surgeries…
Brain Navi has officially landed in Spain! TAIPEI, Aug. 11, 2025 -- Such an achievement has been made possible through the first of many collaborations with our valued partner, Palex Healthcare. This milestone has been reached not only thanks to Palex's solid reputation and deep experience in the Spanish medical market, but also due to the trust and commitment of their team. Brain Navi CEO Jerry Chen stated, "Brain Navi is proud to work alongside a partner that shares our vision of surgical innovation and desire to improve the well-being of patients continuously."&nbs
- 김갑성 기자
- 2025-08-11 09:00
-
Hugel launches botulinum toxin Letybo in Malaysia
- The company strengthens brand experience for local medical professionals through academic events and hands-on workshops - It will solidify the market position of premium toxin products through Malaysian partner Venusys Medical SEOUL, South Korea, Aug. 11, 2025 -- Hugel Inc., a leading global medical aesthetics company chaired by Suk Cha, has officially launched its botulinum toxin product Letybo in Malaysia – an emerging market for medical aesthetics in Southeast Asia. The company's Malaysian partner Venusys Medical Sdn Bhd introduced Letybo at the
- 김갑성 기자
- 2025-08-11 08:30
-
Anbio Biotechnology Responds to Global Outbreaks with Ch…
[ 메디채널 김갑성 기자 ] Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide. FRANKFURT, Germany, Aug. 9, 2025 -- In response to recent outbreaks of Chikungunya fever, Anbio Biotechnology has announced the launch of its Chikungunya IgM/IgG Rapid Test, offering clinicians and public health authorities a fast, accessible diagnostic tool at the point of care. As cases continue to rise across tropical and subtropical regions, timely detection and differentiation from other arboviral
- 김갑성 기자
- 2025-08-09 09:30
-
Spirit AeroSystems Announces Definitive Agreement with CTRM…
WICHITA, Kan., Aug. 9, 2025 -- Today, Spirit AeroSystems Holdings, Inc. (NYSE: SPR) announces a purchase agreement to sell its facility and businesses in Subang, Malaysia to Composites Technology Research Malaysia Sdn Bhd ("CTRM") for $95,200,000, subject to customary adjustments. This transaction was entered into following the previously announced merger agreement with Boeing and subsequent definitive agreement with Airbus. The transaction is expected to close in the 4th quarter of 2025, subject to regulatory approvals and closing conditions being met. Spirit AeroSys
- 김갑성 기자
- 2025-08-09 04:43
-
GenScript Unveils New Global Identity: "Scripting Possibilities"…
PISCATAWAY, N.J., Aug. 8, 2025 -- GenScript Biotech Corporation (HK.1548), a global leader in life sciences innovation, today unveiled its new global brand platform: Scripting Possibilities—a future-forward identity designed to match the speed, complexity, and promise of modern biotechnology. The brand relaunch reflects GenScript's ambition to become the most trusted partner for researchers worldwide—delivering scientific accelerations from discovery to manufacturing with speed, precision, and purpose. The new platform, visual identity, and tagline roll out globally today, on GenScript
- 김갑성 기자
- 2025-08-08 20:30
-
Career-switching professionals, twins and trailblazers: Du…
[ 메디채널 김갑성 기자 ] 78 students embark on their journey to become doctors at Duke-NUS Medical School's 19th White Coat Ceremony 46 individuals have made the shift from other careers into medicine, including a lawyer with experience as a yoga coach, a software engineer and professionals from diverse paths, underscoring Duke-NUS' distinct positioning as Singapore's only graduate-entry medical school For the first time, twin sisters enter the MD programme together SINGAPORE, Aug. 8, 2025 -- A new chapter in Singapore's healthcare story began today as 78 aspiring doctors from Duke-NUS
- 김갑성 기자
- 2025-08-08 19:51
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-10-24_FRI
- TECNO Announces the Winners of the 2025 Shot On CAMON Global Photography Contest -- Capturing the Pulse, the Bond, and the Motion of Life 14:00
- CU Malaysia and aT Kuala Lumpur Center Strengthen Partnership to Promote K-Food Nationwide 13:39
- Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/αvβ6 Bispecfic ADC JSKN022 12:56
- Neolix Raises US$600+ Million in Series D, Setting New Record for China's Autonomous Driving Industry 11:56
- Nova Technology Upgrades AI Claim Agent, Driving Next-Generation Intelligent Claims 11:41
- CNN's 'Tech for Good' showcases young innovators redefining rescue missions with robotics 11:26
- Neolix Raises US$600+ Million in Series D Funding, Setting New Record for Private Financing of China's Autonomous Driving Industry 11:20
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 10월 24일 15시 40분